BeatVecNet classifies drug-induced contractile phenotypes from beat-gated motion vectors in micropatterned human induced pluripotent stem cell-derived cardiomyocytes.

Authors

Shigeyuki Magi, Yasunari Kanda, Atsuhiko T Naito

Published in

British journal of pharmacology. Oct 13, 2026. Epub Oct 13, 2026.

Abstract

Assessment of electrophysiological cardiotoxicity in vitro has advanced, yet scalable assays for contractile dysfunction remain limited. BeatVecNet, an interpretable deep-learning framework, classifies drug-induced contractile phenotypes from beat-gated motion vectors in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).
BeatVecNet was developed and evaluated using beat-gated motion-vector tensors derived from hiPSC-CMs recorded by label-free phase-contrast imaging at 150 fps. hiPSC-CMs were cultured on micropatterned substrates to provide a consistent contraction axis for directional motion analysis. Dense optical flow was used to derive motion vectors, which were retained as beat-gated spatiotemporal tensors rather than reduced to scalar traces. The model uses two convolutional branches to process horizontal and vertical velocity components separately and was evaluated on independent assays containing control, doxorubicin, trastuzumab and sunitinib.
BeatVecNet distinguished drug-induced contractile phenotypes with a macro-F1 of 0.916, outperforming conventional kinematic classifiers (best baseline 0.706), with the largest advantage at low doses. Branch-replacement ablation indicated non-redundant contributions of horizontal and vertical motion components, with trastuzumab classification showing greater sensitivity to horizontal-component replacement and sunitinib classification to vertical-component replacement. Phase-resolved attribution further identified temporal patterns within the beat cycle not explained by peak velocity alone. Micropatterning improved signal consistency and contractile coherence, enabling robust directional motion analysis.
BeatVecNet extracts drug-associated contractile signatures not captured by conventional scalar analysis while providing direction- and phase-resolved interpretability at the motion-representation level. This platform complements electrophysiology-centred safety assessment and provides proof of concept for classification of subtle drug-induced contractile phenotypes.

PMID:
42867314
Bibliographic data and abstract were imported from PubMed on 14 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.